224 related articles for article (PubMed ID: 37258531)
1. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.
M Naeini M; Newell F; Aoude LG; Bonazzi VF; Patel K; Lampe G; Koufariotis LT; Lakis V; Addala V; Kondrashova O; Johnston RL; Sharma S; Brosda S; Holmes O; Leonard C; Wood S; Xu Q; Thomas J; Walpole E; Tao Mai G; Ackland SP; Martin J; Burge M; Finch R; Karapetis CS; Shannon J; Nott L; Bohmer R; Wilson K; Barnes E; Zalcberg JR; Mark Smithers B; Simes J; Price T; Gebski V; Nones K; Watson DI; Pearson JV; Barbour AP; Waddell N
Nat Commun; 2023 May; 14(1):3155. PubMed ID: 37258531
[TBL] [Abstract][Full Text] [Related]
2. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
[TBL] [Abstract][Full Text] [Related]
3. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Barbour AP; Walpole ET; Mai GT; Barnes EH; Watson DI; Ackland SP; Martin JM; Burge M; Finch R; Karapetis CS; Shannon J; Nott LM; Varma S; Marx G; Falk GL; Gebski V; Oostendorp M; Wilson K; Thomas J; Lampe G; Zalcberg JR; Simes J; Smithers BM;
Ann Oncol; 2020 Feb; 31(2):236-245. PubMed ID: 31959340
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.
Mercieca-Bebber R; Barnes EH; Wilson K; Samoon Z; Walpole E; Mai T; Ackland S; Burge M; Dickie G; Watson D; Leung J; Wang T; Bohmer R; Cameron D; Simes J; Gebski V; Smithers M; Thomas J; Zalcberg J; Barbour AP
BMC Cancer; 2022 Mar; 22(1):276. PubMed ID: 35291965
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Aichler M; Motschmann M; Jütting U; Luber B; Becker K; Ott K; Lordick F; Langer R; Feith M; Siewert JR; Walch A
Oncotarget; 2014 Aug; 5(16):6620-32. PubMed ID: 25216514
[TBL] [Abstract][Full Text] [Related]
7. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
8. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.
Hao D; He S; Harada K; Pizzi MP; Lu Y; Guan P; Chen L; Wang R; Zhang S; Sewastjanow-Silva M; Abdelhakeem A; Shanbhag N; Bhutani M; Han G; Lee JH; Zhao S; Weston B; Blum Murphy M; Waters R; Estrella JS; Roy-Chowdhuri S; Gan Q; Lee JS; Peng G; Hanash SM; Calin GA; Song X; Zhang J; Song S; Wang L; Ajani JA
Gut; 2021 Nov; 70(11):2055-2065. PubMed ID: 33334899
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract][Full Text] [Related]
10. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim A; Ylstra B; van Essen HF; Benner C; Stenning S; Langley R; Allum W; Cunningham D; Inam I; Hewitt LC; West NP; Meijer GA; van de Wiel MA; Grabsch HI
Oncotarget; 2016 Jul; 7(28):44084-44095. PubMed ID: 27286451
[TBL] [Abstract][Full Text] [Related]
11. Prospective cohort study of neoadjuvant therapy toxicity in the treatment of oesophageal adenocarcinoma.
Bunting D; Berrisford R; Wheatley T; Humphreys L; Ariyarathenam A; Sanders G
Int J Surg; 2018 Apr; 52():126-130. PubMed ID: 29455047
[TBL] [Abstract][Full Text] [Related]
12. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
13. The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
Sihag S; Nussenzweig SC; Walch HS; Hsu M; Tan KS; De La Torre S; Janjigian YY; Maron SB; Ku GY; Tang LH; Shah PM; Wu A; Jones DR; Solit DB; Schultz N; Ganesh K; Berger MF; Molena D
Clin Cancer Res; 2022 Jun; 28(12):2669-2678. PubMed ID: 35377946
[TBL] [Abstract][Full Text] [Related]
14. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
15. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
Aichler M; Elsner M; Ludyga N; Feuchtinger A; Zangen V; Maier SK; Balluff B; Schöne C; Hierber L; Braselmann H; Meding S; Rauser S; Zischka H; Aubele M; Schmitt M; Feith M; Hauck SM; Ueffing M; Langer R; Kuster B; Zitzelsberger H; Höfler H; Walch AK
J Pathol; 2013 Aug; 230(4):410-9. PubMed ID: 23592244
[TBL] [Abstract][Full Text] [Related]
16. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
17. Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma.
Abbas S; Pich O; Devonshire G; Zamani SA; Katz-Summercorn A; Killcoyne S; Cheah C; Nutzinger B; Grehan N; Lopez-Bigas N; ; Fitzgerald RC; Secrier M
Nat Commun; 2023 Jul; 14(1):4239. PubMed ID: 37454136
[TBL] [Abstract][Full Text] [Related]
18. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract][Full Text] [Related]
19. The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy.
Croft W; Evans RPT; Pearce H; Elshafie M; Griffiths EA; Moss P
Mol Cancer; 2022 Oct; 21(1):200. PubMed ID: 36253784
[TBL] [Abstract][Full Text] [Related]
20. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
